Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

被引：0
|
作者：
Perol, M. [1 ]
Filleron, T. [2 ]
Quantin, X. [3 ]
Chouaid, C. [4 ]
Valette, C. Audigier [5 ]
Lena, H. [6 ]
Kaderbhai, C. [7 ]
Fabre, C. [8 ]
Santorelli, M. [9 ]
Bensimon, L. [10 ]
Burke, T. [11 ]
Couch, D. [12 ]
Nguyen, E. [12 ]
Courtinard, C. [12 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] Ctr Claudius Regaud, Biostat, Toulouse, France
[3] ICM Reg Canc Inst Montpellier, Montpellier, France
[4] CH Intercommunal Creteil, Creteil, France
[5] Hop St Musse, Toulon, France
[6] CHU Pontchaillou, Rennes, France
[7] Ctr Georges Francois Leclerc, Dijon, France
[8] IQVIA Co France, Capionis, Courbevoie, France
[9] Merck & Co Inc, Rahway, NJ USA
[10] MSD France, Dir Ass Evaluat Med Econ & Epidemiol, Puteaux La Defense, France
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] UNICANCER, Data Off, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
109P
引用
收藏
页码：S757 / S758
页数：2
相关论文
共 50 条
  • [1] Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France
    Perol, M.
    Quantin, X.
    Lena, H.
    Filleron, T.
    Chouaid, C.
    Valette, C. Audigier
    Kaderbhai, C.
    Chenuc, G.
    Santorelli, M.
    Bensimon, L.
    Burke, T.
    Simon, G.
    Martin, A-L.
    Debieuvre, D.
    Gervais, R.
    Schott, R.
    Carton, M.
    Courtinard, C.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S758
  • [2] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
    Goto, Y.
    Santorelli, M. L.
    Taniguchi, K.
    Kamitani, T.
    Irisawa, M.
    Kanda, K.
    Abe, M.
    Burke, T.
    Nokihara, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
  • [3] First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
    Amrane, K.
    Geier, M.
    Corre, R.
    Leveiller, G.
    Florence, G.
    Lamy, R.
    Bizec, J. L.
    Goarant, E.
    Robinet, G.
    Ulrike, S.
    Quere, G.
    Bernier, C.
    Descourt, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [5] 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
    Velcheti, Vamsidhar
    Rai, Pragya
    Kao, Yu-Han
    Chirovsky, Diana
    Nunes, Ana Tablante
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [6] Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Shibaki, Ryota
    Matsumoto, Yuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Motoi, Noriko
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2021, 22 (02) : 127 - +
  • [7] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
  • [8] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [9] Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Piperdi, Bilal
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (18) : 1541 - 1554
  • [10] Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data
    Velcheti, V.
    Hu, X.
    Li, Y.
    Burke, T.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S755 - S755
12345